What are the other Names for this Condition? (Also known as/Synonyms)

• DITRA (Deficiency of the Interleukin-36-Receptor Antagonist)
• Interleukin-36-Receptor Antagonist Deficiency

What is Deficiency of the Interleukin-36-Receptor Antagonist? (Definition/Background Information)

• Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) is a rare autoinflammatory disorder characterized by recurrent episodes of inflammation, primarily affecting the skin, nails, and joints. It is caused by mutations in the IL36RN gene, which provides instructions for producing the interleukin-36 receptor antagonist (IL-36Ra) protein.
• IL-36Ra is a natural inhibitor of the pro-inflammatory signaling pathway mediated by interleukin-36 (IL-36). Mutations in the IL36RN gene lead to a deficiency or dysfunction of IL-36Ra, resulting in uncontrolled activation of the IL-36 pathway and subsequent excessive inflammation.
• The clinical features of Deficiency of the Interleukin-36 Receptor Antagonist typically manifest in infancy or early childhood. The most common manifestations include generalized pustular psoriasis (characterized by widespread pus-filled skin lesions), palmoplantar pustulosis (pustules on the palms and soles), and a form of arthritis known as psoriatic arthritis.
• Various factors, including stress, infections, or certain medications, can trigger episodes of inflammation in Deficiency of the Interleukin-36 Receptor Antagonist. The severity and frequency of episodes can vary among individuals, and affected individuals may experience periods of remission and relapse.
• Early diagnosis of Deficiency of the Interleukin-36 Receptor Antagonist is crucial to guide appropriate management and prevent complications. Treatment focuses on controlling inflammation and alleviating symptoms during episodes. This may include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or other medications targeting the IL-36 pathway.
• Management of Deficiency of the Interleukin-36 Receptor Antagonist often involves a multidisciplinary approach, with dermatologists, rheumatologists, and other healthcare professionals experienced in managing autoinflammatory disorders. Regular monitoring, follow-up, and genetic counseling may also be recommended for affected individuals and their families.
• Deficiency of the Interleukin-36 Receptor Antagonist is a chronic condition requiring long-term management. While treatment can help control symptoms and improve quality of life, no cure is currently available. Ongoing research aims to understand the underlying mechanisms of DITRA further and develop more targeted therapies.

Who gets Deficiency of the Interleukin-36-Receptor Antagonist? (Age and Sex Distribution)

• Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) typically presents in early childhood, although the age of onset can vary. Symptoms often appear within the first year of life, but some cases may manifest later in childhood.
• DITRA does not show a significant gender bias, as the condition can affect males and females.
• Patients have been reported to be of Caucasian, Asian, and African ancestry. Specific countries of note are Spain, Algeria, and Tunisia. The Tunisian port of Sfax has been reported to have a 1 % rate of carriers of the IL36RN gene, with 0.52 % of births having a risk of the disease in this population
• Since DITRA is a rare disorder, the precise prevalence and age and sex distribution are not well-defined. However, it is important to note that DITRA is considered a rare condition, and its occurrence is relatively infrequent.

What are the Risk Factors for Deficiency of the Interleukin-36-Receptor Antagonist? (Predisposing Factors)

The primary risk factor for Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) is the presence of mutations in the IL36RN gene. It is an autosomal recessive disorder, which means that both copies of the IL36RN gene need to have mutations for the condition to occur.

• A family history of DITRA or parents carrying one mutated copy of the IL36RN gene increases the risk of inheriting the disorder. Carriers of a single mutated gene copy typically do not exhibit symptoms of DITRA but can pass the mutation on to their children.
• The risk for DITRA is particularly high in and near the Tunisian port city of Sfax and in those who have immigrated elsewhere from this city.

However, DITRA is a rare disorder, and the precise risk factors and prevalence rates are not well-defined due to its rarity.

It is important to note that having a risk factor does not mean that one will get the condition. A risk factor increases one’s chances of getting a condition compared to an individual without the risk factors. Some risk factors are more important than others.

Also, not having a risk factor does not mean that an individual will not get the condition. It is always important to discuss the effect of risk factors with your healthcare provider.

What are the Causes of Deficiency of the Interleukin-36-Receptor Antagonist? (Etiology)

The primary cause of Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) is mutations in the IL36RN gene. The IL36RN gene provides instructions for producing the interleukin-36 receptor antagonist (IL-36Ra) protein, which acts as a natural inhibitor of the pro-inflammatory signaling pathway mediated by interleukin-36 (IL-36).

Mutations in the IL36RN gene can lead to a deficiency or dysfunction of the IL-36Ra protein, resulting in uncontrolled activation of the IL-36 pathway and subsequent excessive inflammation. This dysregulated immune response contributes to the characteristic symptoms of DITRA, including recurrent episodes of inflammation primarily affecting the skin, nails, and joints.

DITRA follows an autosomal recessive inheritance pattern, meaning that both copies of the IL36RN gene need mutations for the condition to occur. Individuals who inherit one mutated copy of the gene are carriers and typically do not exhibit symptoms but can pass the mutation on to their children.

The specific types of mutations in the IL36RN gene can vary among individuals with DITRA, and the impact of these mutations on the production and function of the IL-36Ra protein may also vary. Further research is needed to understand the full spectrum of genetic mutations associated with DITRA and their effects on IL-36 signaling.

It is important to note that genetic mutations primarily cause Deficiency of the Interleukin-36 Receptor Antagonist, and the disorder is not related to external factors or environmental triggers. Early recognition and diagnosis of DITRA through genetic testing can help guide appropriate management and treatment strategies for affected individuals and their families.

What are the Signs and Symptoms of Deficiency of the Interleukin-36-Receptor Antagonist?

Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) is characterized by recurrent episodes of inflammation, primarily affecting the skin, nails, and joints. The signs and symptoms of DITRA can vary among individuals but commonly include:

• Skin Inflammation: Episodes of skin inflammation (generalized pustular psoriasis) are a hallmark feature of DITRA. This can present as redness, swelling, and the formation of painful pustules or plaques on the skin. The skin involvement can be widespread or localized to specific body areas. Pustular psoriasis can present as clusters of pustules, ruptured pustules, or diffuse distributed redness. Vasodilation makes the skin emit heat. The disrupted skin barrier permits increased fluid loss. Inflamed skin also carries a risk for septicemia (bloodstream infection).
• Nail Abnormalities: Nail abnormalities are frequently observed in DITRA. These can include pitting, ridges, thickening, or discoloration of the nails. In severe cases, nail shedding or destruction may occur.
• Other Skin Manifestations: In addition to pustules and plaques, other skin manifestations may be present, such as erythema (redness), scales, or blistering.
• Joint Inflammation: Joint inflammation, or arthritis, can occur during episodes of DITRA. The joints may become swollen, tender, and painful, limiting movement and causing discomfort.
• Cardiovascular: abnormal fluid loss through the inflamed skin can lead to electrolyte imbalances, tachycardia (rapid heart rate),  low-volume heart failure, and cardiac arrest.
• Abdominal: Nausea results with flares. Appetite loss is common. Liver and renal (kidney) dysfunction can result.
• Recurrent Episodes: DITRA is characterized by recurrent episodes of inflammation and symptoms. The episodes can vary in duration and frequency, with periods of remission and relapse.
• General Symptoms: During episodes, individuals with DITRA may experience general symptoms such as fever, fatigue, and malaise. The increased inflammatory mediators and heat loss can lead to shaking chills. Headache and asthenia (muscle weakness) are also seen.

The severity and frequency of episodes can vary among individuals with DITRA. Some individuals may experience mild and infrequent episodes, while others may have more severe and frequent manifestations.

How is Deficiency of the Interleukin-36-Receptor Antagonist Diagnosed?

The diagnosis of Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) involves a combination of clinical evaluation, genetic testing, and exclusion of other possible causes of recurrent inflammation. Here are the steps involved in diagnosing DITRA:

• Clinical Evaluation: A thorough medical history is taken to assess the pattern, frequency, and duration of episodes, along with specific symptoms such as skin inflammation, nail abnormalities, and joint involvement. A physical examination is conducted to identify characteristic signs and symptoms of DITRA.
• Genetic Testing: Genetic testing is a key component of the diagnostic process for DITRA. It involves analyzing the IL36RN gene for mutations. A blood sample is collected, and DNA sequencing or other molecular genetic techniques are used to identify mutations in the IL36RN gene. The presence of mutations confirms the diagnosis of DITRA.
• Exclusion of Other Conditions: Since the symptoms of DITRA can overlap with other inflammatory disorders, it is important to exclude other potential causes of recurrent inflammation. Additional laboratory tests, imaging studies, or consultations with specialists may be conducted based on the specific presentation.
• Family History: A family history of DITRA or other autoinflammatory disorders can provide valuable information for the diagnosis. Inquiring about similar symptoms or consanguinity (shared blood relationship) in the family can be helpful.

DITRA is a rare disorder, and its diagnosis may require specialized expertise in autoinflammatory diseases. Consulting with a healthcare professional or dermatologist experienced in diagnosing and managing autoinflammatory disorders is advised.

Early diagnosis of Deficiency of the Interleukin-36 Receptor Antagonist is crucial to guide appropriate management and treatment strategies. Genetic testing can provide a definitive diagnosis and assist in determining the appropriate treatment approach for affected individuals.

Many clinical conditions may have similar signs and symptoms. Your healthcare provider may perform additional tests to rule out other clinical conditions to arrive at a definitive diagnosis.

What are the possible Complications of Deficiency of the Interleukin-36-Receptor Antagonist?

Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) can be associated with various complications, which may vary among individuals. Some possible complications of DITRA include:

• Secondary Infections: During episodes of skin inflammation and compromised skin barrier, individuals with DITRA may be more susceptible to secondary bacterial or fungal infections. Prompt recognition and management of infections are important to prevent complications and minimize the risk of severe infections. Septicemia (disseminated bloodstream infection) can potentially lead to fatalities.
• Skin Damage and Scarring: Severe episodes of skin inflammation in DITRA can result in skin damage, including scarring and pigmentation changes. The repeated cycle of inflammation and healing can permanently alter the skin's appearance and texture.
• Joint Damage: Recurrent episodes of arthritis in DITRA can contribute to joint damage over time. Persistent inflammation can result in cartilage destruction, joint deformities, and functional limitations.
• Nail Abnormalities: Nail involvement in DITRA can significantly change nail structure and appearance. Severe nail abnormalities may cause discomfort, functional impairment, and affect an individual's self-esteem.
• Fluid loss and electrolyte imbalances can lead to stress on the cardiovascular system, leading to cardiac infarction or arrest.
• Psychosocial Impact: The chronic nature of DITRA and its impact on physical appearance, daily functioning, and quality of life can have psychological and emotional consequences. Individuals with DITRA may experience anxiety, depression, social isolation, and reduced quality of life.
• Systemic Inflammation: Although DITRA primarily affects the skin, nails, and joints, there have been reports of systemic inflammation and involvement of other organs. This can lead to complications in various body systems, although the frequency and severity of systemic involvement may vary among individuals. All diseases with generalized increased inflammation lead to fever and overall feelings of malaise, weakness,  and aches in muscles and joints.

Not all individuals with Deficiency of the Interleukin-36 Receptor Antagonist will experience these complications. The severity and occurrence of complications can vary based on the individual's specific disease manifestations, response to treatment, and other factors.

Timely intervention and appropriate treatment can help minimize the impact of complications and optimize long-term outcomes for individuals with DITRA.

How is Deficiency of the Interleukin-36-Receptor Antagonist Treated?

The treatment of Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) aims to control inflammation, reduce the frequency and severity of episodes, alleviate symptoms, and prevent complications. The treatment approach may vary depending on the individual's symptoms, disease severity, and therapy response. Here are some common treatment strategies for DITRA:

• Topical Treatments: During episodes of skin inflammation, topical treatments such as corticosteroid creams or ointments may be prescribed to reduce inflammation and alleviate symptoms.
• Systemic Medications: In more severe cases or when topical treatments are insufficient, systemic medications may control inflammation. These can include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or immunosuppressive agents, such as methotrexate and cyclosporin, which are used in pustular psoriasis also. Aromatic retinoids such as acitretin can be effective in pustular forms of psoriasis. Oral aromatic retinoid medications can lead to birth defects and should not be used in women who are pregnant or might get pregnant. The choice of medication depends on individual factors and treatment response.
• Biologic Agents: Biologic therapies targeting specific molecules or pathways involved in inflammation may be considered for individuals with severe or refractory DITRA. Biologic agents such as IL-1 inhibitors (e.g., anakinra) or IL-17 inhibitors (e.g., secukinumab) have shown some efficacy in managing DITRA symptoms. The FDA approved Spesolimab-sbzo (in September 2022) for the treatment of generalized pustular psoriasis (GPP). Approval was for use in adults. Spesolimab-sbzo works by decreasing inflammation caused by the abnormal IL-36 pathway
• Symptom Management: Supportive measures, such as pain management with analgesics or joint protection techniques, can help alleviate symptoms and improve quality of life. Physical and occupational therapy may also be beneficial for managing joint symptoms and improving functional abilities.
• Infection Prevention: Due to the risk of secondary infections during episodes of inflammation, preventive measures such as good hygiene practices and prompt management of skin lesions are important to reduce the risk of infections.
• Genetic Counseling: Genetic counseling may be recommended for affected individuals and their families to provide information about the inheritance pattern, assess the risk of passing on the mutation, and make informed decisions regarding family planning.

The treatment of DITRA is often individualized based on the specific needs and symptoms of the individual. Regular monitoring, follow-up appointments, and communication with healthcare professionals experienced in managing autoinflammatory disorders, such as dermatologists and rheumatologists, are crucial for ongoing care, treatment adjustments, and evaluation of treatment response.

Collaboration with healthcare professionals, adherence to treatment recommendations, and proactive management of symptoms are key factors in managing Deficiency of the Interleukin-36 Receptor Antagonist and improving outcomes and quality of life for affected individuals.

How can Deficiency of the Interleukin-36-Receptor Antagonist be Prevented?

Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) is a genetic disorder caused by mutations in the IL36RN gene. As such, it is not currently possible to prevent the development of DITRA since the underlying genetic mutations are inherited.

However, there are strategies to manage and minimize the impact of DITRA on an individual's life. These strategies focus on early diagnosis, prompt treatment, and preventive measures to reduce the frequency and severity of episodes, prevent complications, and enhance overall well-being. Here are some measures that can be taken:

• Early Diagnosis and Treatment: Early recognition and diagnosis of DITRA are crucial to initiate appropriate treatment and preventive measures. If you suspect DITRA or have concerns about specific symptoms, it is important to consult with a healthcare professional or dermatologist experienced in diagnosing and managing autoinflammatory disorders.
• Regular Monitoring and Follow-up: Regular monitoring and follow-up appointments with healthcare professionals are essential for ongoing care and treatment optimization. Regular assessments can help identify any changes in disease activity, adjust treatment plans as needed, and prevent complications.
• Treatment Adherence: Adhering to the prescribed treatment plan is important for managing DITRA effectively. This includes taking medications as directed, attending follow-up appointments, and communicating any changes or concerns to your healthcare team.
• Lifestyle Measures: Leading a healthy lifestyle can support overall well-being and potentially reduce the impact of DITRA. This includes maintaining a balanced diet, exercising regularly, managing stress levels, getting adequate sleep, and avoiding known triggers that may exacerbate symptoms.
• Infection Prevention: During episodes of inflammation and compromised skin barrier, individuals with DITRA may be more susceptible to secondary infections. Practicing good hygiene, such as regular handwashing, avoiding close contact with individuals with infectious illnesses, and staying up to date with vaccinations, can help reduce the risk of infections.
• Genetic Counseling: If you have a family history of DITRA or other autoinflammatory disorders, genetic counseling can provide information about the condition, assess the risk of passing on the mutation, and guide family planning decisions.

While these measures can help manage Deficiency of the Interleukin-36 Receptor Antagonist and reduce the impact of the condition, it's important to note that DITRA is a lifelong condition, and complete prevention of episodes or complications may not be possible. Collaboration with healthcare professionals and adherence to recommended treatment and lifestyle measures are essential for optimizing outcomes and maintaining the best possible quality of life.

In addition, ongoing research and medical advancements in autoinflammatory disorders may contribute to better understanding, improved treatments, and potential preventive strategies in the future.

What is the Prognosis of Deficiency of the Interleukin-36-Receptor Antagonist? (Outcomes/Resolutions)

The prognosis of Deficiency of the Interleukin-36 Receptor Antagonist (DITRA) can vary among individuals and is influenced by several factors, including the severity and frequency of episodes, response to treatment, and the occurrence of complications. Some considerations regarding the prognosis of DITRA include:

• Variable Disease Course: The course of DITRA can vary significantly among individuals. Some individuals may experience relatively mild and infrequent episodes, while others may have more severe and frequent manifestations. The disease course can also change over time, with periods of remission and relapse.
• Treatment Response: Early diagnosis and appropriate treatment can significantly improve outcomes for individuals with DITRA. With the right treatment approach, many individuals can achieve symptom control, reduce the frequency and severity of episodes, and lead productive lives. However, treatment response can vary, and some individuals may require ongoing management of symptoms.
• Complications, such as secondary infections, joint damage, or skin scarring, can influence the long-term prognosis of DITRA. Prompt diagnosis, timely management, and regular monitoring are important to detect and manage complications early, minimizing their impact on overall health.
• Quality of Life: DITRA can significantly impact an individual's quality of life during episodes of inflammation. The symptoms and unpredictable nature of the condition and associated physical and psychological challenges can affect daily activities, social interactions, and emotional well-being.
• Research and Advances: Ongoing research and medical advancements contribute to a better understanding of DITRA and may lead to improved treatments and outcomes in the future.

The prognosis of Deficiency of the Interleukin-36 Receptor Antagonist can vary among individuals, and it is challenging to predict the long-term outcomes with certainty. Early diagnosis, appropriate management, and regular follow-up with healthcare professionals experienced in managing autoinflammatory disorders, such as dermatologists and rheumatologists, are crucial for optimizing outcomes and maintaining the best possible quality of life.

Regular monitoring, follow-up appointments, and communication with healthcare professionals experienced in managing autoinflammatory disorders are essential for ongoing care, treatment adjustments, and evaluation of treatment response.

Additional and Relevant Useful Information for Deficiency of the Interleukin-36-Receptor Antagonist:

The following DoveMed website link is a useful resource for additional information:

http://www.dovemed.com/diseases-conditions/rare-disorders/